3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Conditions
Multiple Myeloma
60
Lymphoma
56
Leukemia, Myeloid, Acute
51
Leukemia
50
Lymphoma, Non-Hodgkin
48
Precursor Cell Lymphoblastic Leukemia-Lymphoma
46
Hodgkin Disease
36
Myelodysplastic Syndromes
28
Lymphoma, Large B-Cell, Diffuse
27
Breast Neoplasms
24
Lymphoma, Mantle-Cell
23
Neuroblastoma
22
Leukemia, Lymphocytic, Chronic, B-Cell
22
Burkitt Lymphoma
17
Lymphoma, Follicular
16
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
16
Central Nervous System Neoplasms
13
Lymphoma, Large-Cell, Immunoblastic
12
Sarcoma
11
Neoplasms, Plasma Cell
11
Brain Neoplasms
11
Recurrence
10
Lymphoma, B-Cell, Marginal Zone
10
Neoplasms
9
Hematologic Neoplasms
9
Congenital Abnormalities
9
Myeloproliferative Disorders
8
Leukemia, Myelomonocytic, Chronic
8
Leukemia, Biphenotypic, Acute
8
Graft vs Host Disease
8
Interventions
pegylated granulocyte colony-stimulating factor, human
2
Granulocyte Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Chemotherapy Induced Neutropenia
×
Granulocyte Colony-Stimulating Factor
×
Clear all
NCT01674855
2014-10-01
PEG-G-CSF
Dong-A ST Co., Ltd.
Phase 3
Completed
74 enrolled
NCT01923545
2014-10-01
PEG-G-CSF
Dong-A ST Co., Ltd.
Phase 2
Completed
61 enrolled